{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360580240139457280.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1038/s41571-020-0352-8"}},{"identifier":{"@type":"URI","@value":"http://www.nature.com/articles/s41571-020-0352-8.pdf"}},{"identifier":{"@type":"URI","@value":"http://www.nature.com/articles/s41571-020-0352-8"}}],"dc:title":[{"@value":"Moving towards personalized treatments of immune-related adverse events"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380580240139457281","@type":"Researcher","foaf:name":[{"@value":"Khashayar Esfahani"}]},{"@id":"https://cir.nii.ac.jp/crid/1380580240139457286","@type":"Researcher","foaf:name":[{"@value":"Arielle Elkrief"}]},{"@id":"https://cir.nii.ac.jp/crid/1380580240139457280","@type":"Researcher","foaf:name":[{"@value":"Cassandra Calabrese"}]},{"@id":"https://cir.nii.ac.jp/crid/1380580240139457282","@type":"Researcher","foaf:name":[{"@value":"Réjean Lapointe"}]},{"@id":"https://cir.nii.ac.jp/crid/1380580240139457285","@type":"Researcher","foaf:name":[{"@value":"Marie Hudson"}]},{"@id":"https://cir.nii.ac.jp/crid/1380580240139457287","@type":"Researcher","foaf:name":[{"@value":"Bertrand Routy"}]},{"@id":"https://cir.nii.ac.jp/crid/1380580240139457283","@type":"Researcher","foaf:name":[{"@value":"Wilson H. Miller"}]},{"@id":"https://cir.nii.ac.jp/crid/1380580240139457284","@type":"Researcher","foaf:name":[{"@value":"Leonard Calabrese"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"17594774"},{"@type":"EISSN","@value":"17594782"}],"prism:publicationName":[{"@value":"Nature Reviews Clinical Oncology"}],"dc:publisher":[{"@value":"Springer Science and Business Media LLC"}],"prism:publicationDate":"2020-04-03","prism:volume":"17","prism:number":"8","prism:startingPage":"504","prism:endingPage":"515"},"reviewed":"false","dc:rights":["http://www.springer.com/tdm","http://www.springer.com/tdm"],"url":[{"@id":"http://www.nature.com/articles/s41571-020-0352-8.pdf"},{"@id":"http://www.nature.com/articles/s41571-020-0352-8"}],"createdAt":"2020-04-03","modifiedAt":"2023-05-20","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050574257199662848","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Aging-associated and CD4 T-cell–dependent ectopic CXCL13 activation predisposes to anti–PD-1 therapy-induced adverse events"}]},{"@id":"https://cir.nii.ac.jp/crid/1360017279860436224","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity"}]},{"@id":"https://cir.nii.ac.jp/crid/1360302864787845376","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Association of CD8 + T cells expressing nivolumab-free PD-1 with clinical status in a patient with relapsed refractory classical Hodgkin lymphoma"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1038/s41571-020-0352-8"},{"@type":"CROSSREF","@value":"10.1016/j.ccell.2022.04.004_references_DOI_KJmQVEycZQZsS9YVOck8dwmpLSU"},{"@type":"CROSSREF","@value":"10.1073/pnas.2205378119_references_DOI_KJmQVEycZQZsS9YVOck8dwmpLSU"},{"@type":"CROSSREF","@value":"10.1007/s12185-023-03644-5_references_DOI_KJmQVEycZQZsS9YVOck8dwmpLSU"}]}